ABSTRACT
HLA-A*24:391 differs from HLA-A*24:02:01:01 by one nucleotide substitution at position 33.
Subject(s)
Alleles , HLA-A Antigens/genetics , Histocompatibility Testing/methods , Base Sequence , Exons/genetics , HumansABSTRACT
HLA-C*16:116 differs from HLA-C*16:01:01:01 by single-nucleotide substitution at position 30.
Subject(s)
Alleles , HLA-C Antigens/genetics , Histocompatibility Testing/methods , Sequence Analysis, DNA , Base Sequence , Exons/genetics , Humans , Sequence AlignmentABSTRACT
HLA-B*07:305 differs from HLA-B*07:02:01:01 by one nucleotide substitution at position 255.
Subject(s)
Alleles , HLA-B7 Antigen/genetics , Histocompatibility Testing/methods , Sequence Analysis, DNA , Base Sequence , Exons/genetics , Humans , Sequence AlignmentABSTRACT
We have conducted a retrospective study on 251 patients from three centers in France and Switzerland between 2004 and 2010 with the goal to evaluate the impact of HLA-DRB3/B4/B5 allele mismatching after HLA-10/10-matched unrelated allogeneic hematopoietic stem cell transplantation (HSCT). Fourteen (5.5%) patients receiving HSCT from an HLA-10/10-matched unrelated donor had a mismatched DRB4 donor, 23 (9.5%) patients had a mismatched DRB3 donor and 214 (85%) had a fully matched unrelated donor (HLA-10/10) without DRB3- or DRB4-mismatched donor. We compared the outcomes of 37 patients with a DRB3 or DRB4 mismatch with the rest of the population. The median survival for a patient without DRB3/4 mismatch was 18 months (95% confidence interval (CI), 13-29), for DRB3-mismatched patients 32 months (95% CI, 13-NR) and for DRB4-mismatched patients 7 months (95% CI, 3-NR). The multivariate analysis showed a significant impact of DRB4 mismatching on survival (Hazards ratio (HR)=2.1 (95% CI, 1.01-4.67), P=0.045), acute GvHD (HR=2.66 (95% CI, 0.99-7.09) P=0.05) and on transplant-related mortality (HR=2.8; (95% CI, 1.7-4.4) P=0.024). In the view of an impact of DRB4 locus mismatch on clinical outcome, it would be important to confirm this observation in a prospective study as it may be worth considering DRB4 in the unrelated donor selection.
Subject(s)
HLA-DRB4 Chains/immunology , Hematopoietic Stem Cell Transplantation/methods , Histocompatibility/immunology , Transplantation Conditioning/methods , Transplantation, Homologous/methods , Female , France , Histocompatibility Testing , Humans , Male , Retrospective Studies , Survival Analysis , Switzerland , Treatment Outcome , Unrelated DonorsABSTRACT
A novel HLA-B allele, B*39:93, was identified in a French family.
Subject(s)
Alleles , HLA-B Antigens/genetics , Molecular Typing , Base Sequence , Exons , Family , Female , France , Humans , Male , Molecular Sequence Data , Sequence AlignmentSubject(s)
Exons/genetics , HLA-C Antigens/genetics , Hematopoietic Stem Cell Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Base Sequence , France , Histocompatibility , Histocompatibility Testing , Humans , Molecular Sequence Data , Polymorphism, Single Nucleotide , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Sequence Alignment , TransplantationABSTRACT
In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) set up the third annual series of workshops which brought together practitioners from all member centers and took place in October 2012 in Lille. Here we report our results and recommendations regarding the choice of optimal unrelated cord blood unit in terms of cell dose, HLA-matching and other characteristics.
